Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).

被引：0

作者：

Zimmerman, Todd M.

Griffith, Kent A.

Jasielec, Jagoda

Rosenbaum, Cara Ann

McDonnell, Kathryn

Waite-Marin, Jessica

Berdeja, Jesus G.

Raje, Noopur S.

Reece, Donna Ellen

Vij, Ravi

Alonge, Mattina

Rosebeck, Shaun

Gurbuxani, Sandeep

Faham, Malek

Kong, Katherine A.

Levy, Joan

Jakubowiak, Andrzej J.

机构：

[1] Univ Chicago, Chicago, IL 60637 USA

[2] Univ Michigan, Ann Arbor, MI 48109 USA

[3] Northshore Univ Hlth Syst, Evanston, IL USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Massachusetts Gen Hosp, Boston, MA 02114 USA

[6] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[7] Washington Univ, Sch Med, St Louis, MO USA

[8] Sequenta Inc, San Francisco, CA USA

[9] Multiple Myeloma Res Consortium, Norwalk, CT USA

[10] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8510

引用

页数：1